Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tempest Therapeutics Inc.

7.18
-0.1600-2.18%
Volume:4.85K
Turnover:34.80K
Market Cap:25.12M
PE:-0.37
High:7.18
Open:7.12
Low:7.06
Close:7.34
Loading ...

Company Profile

Company Name:
Tempest Therapeutics Inc.
Exchange:
NASDAQ
Establishment Date:
2011
Employees:
24
Office Location:
2000 Sierra Point Parkway,Suite 400,Brisbane,California,United States
Zip Code:
94005
Fax:
- -
Introduction:
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

Directors

Name
Position
Michael Raab
Chairman of the Board
Stephen Brady
Chief Executive Officer and Director
Thomas Dubensky
President and Director
Christine Pellizzari
Director
Geoff Nichol
Director
Ronit Simantov
Director

Shareholders

Name
Position
Stephen Brady
Chief Executive Officer and Director
Nicholas Maestas
Vice President, Strategy and Finance and Corporate Secretary
Samuel Whiting
Executive Vice President and Chief Medical Officer
Thomas Dubensky
President and Director